A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence

Journal of Clinical Psychopharmacology
Raymond F AntonJian Han

Abstract

The purpose of this study was to compare the efficacy and safety of aripiprazole with placebo in the treatment of alcoholics. In this 12-week multicenter, double-blind study, 295 patients with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition alcohol dependence were randomized to treatment with aripiprazole (initiated at 2 mg/d, titrated to a maximum dose of 30 mg/d at day 28) or placebo after screening, wherein patients maintained alcohol abstinence for 3 days or more. The primary efficacy measure was the percentage of days abstinent over 12 weeks. Discontinuations (40.3% vs 26.7%) and treatment-related adverse events (82.8% vs 63.6%) were higher with aripiprazole than with placebo. Mean percentage of days abstinent was similar between aripiprazole and placebo (58.7% vs 63.3%; P = 0.227). Percentage of subjects without a heavy drinking day and the time to first drinking day were also comparable between groups, although the aripiprazole group had fewer drinks per drinking day (4.4 vs 5.5 drinks; P < 0.001). The aripiprazole group showed a larger decrease in percent carbohydrate-deficient transferrin, a biomarker of heavy alcohol consumption at weeks 4 (-14.91% vs -2.23%; P = 0.020) and 8 (-16.92% vs -5.33%; ...Continue Reading

Associated Clinical Trials

References

Jun 1, 1982·Journal of Abnormal Psychology·H A Skinner, B A Allen
Dec 1, 1994·Journal of Studies on Alcohol. Supplement·T F BaborC L Randall
Dec 1, 1994·Journal of Studies on Alcohol. Supplement·W R Miller, F K Del Boca
Oct 8, 1999·Alcoholism, Clinical and Experimental Research·J S RobertsD H Moak
Jul 27, 2000·Annals of the New York Academy of Sciences·G F Koob
Oct 5, 2001·Alcoholism, Clinical and Experimental Research·H R Kranzler, J Van Kirk
Jun 18, 2002·The Journal of Pharmacology and Experimental Therapeutics·Kevin D BurrisPerry B Molinoff
Jun 29, 2004·Clinical Therapeutics·Anthony DeLeonM Lynn Crismon
May 19, 2005·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Mustafa WarsiFrederick Petty
Jul 14, 2005·Journal of Clinical Psychopharmacology·Thomas P BeresfordHenry F Beresford
Oct 15, 2005·Journal of Studies on Alcohol. Supplement·Raymond E Anton, Carrie L Randall
Oct 28, 2005·Nature Neuroscience·George F Koob, Michel Le Moal
Nov 1, 2005·European Journal of Pharmacology·Ingmar H A FrankenWim van den Brink
Nov 4, 2005·European Journal of Pharmacology·Falk Kiefer, Karl Mann
May 4, 2006·JAMA : the Journal of the American Medical Association·Raymond F AntonUNKNOWN COMBINE Study Research Group
May 11, 2006·Alcohol and Alcoholism : International Journal of the Medical Council on Alcoholism·Kimmo IngmanEsa R Korpi

❮ Previous
Next ❯

Citations

Sep 9, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Raymond F AntonDidier Meulien
Jun 24, 2010·Journal of Clinical Psychopharmacology·Hugh MyrickRaymond F Anton
Dec 16, 2010·Addiction Biology·Pia BäckströmPetri Hyytiä
Mar 31, 2012·Addiction Biology·Raye Z LittenAntonio Noronha
Apr 22, 2011·Psychiatry and Clinical Neurosciences·Kazuo YamadaYoshiki Imamura
Feb 28, 2014·CNS Drugs·Carolina L Haass-KofflerGeorge A Kenna
Dec 5, 2015·Expert Opinion on Pharmacotherapy·Jean-Michel AzorinRaoul Belzeaux
Jul 16, 2010·Expert Opinion on Investigational Drugs·Marta Rodríguez-AriasJosé Miñarro
Mar 2, 2016·Substance Abuse : Official Publication of the Association for Medical Education and Research in Substance Abuse·Raye Z LittenJoanne B Fertig
Nov 18, 2009·Pharmacology & Therapeutics·Bianca Jupp, Andrew J Lawrence
Jul 28, 2009·La Presse médicale·Jérôme LacosteNicolas Ballon
Apr 9, 2009·Pharmacology, Biochemistry, and Behavior·Su-xia LiLin Lu
Nov 20, 2015·Progress in Neuro-psychopharmacology & Biological Psychiatry·C E Van SkikeK Nixon
Oct 31, 2015·Progress in Neuro-psychopharmacology & Biological Psychiatry·Laurence LalanneElisabeth Bacon
Sep 11, 2008·Alcoholism, Clinical and Experimental Research·Konstantin VoroninRaymond Anton
Jul 28, 2010·Alcoholism, Clinical and Experimental Research·Daniel FalkRaye Z Litten
Nov 20, 2012·Basic & Clinical Pharmacology & Toxicology·Thercia G VianaFabricio A Moreira
Sep 29, 2011·Alcoholism, Clinical and Experimental Research·Raye Z LittenUNKNOWN NCIG 001 Study Group
Nov 19, 2015·Progress in Neuro-psychopharmacology & Biological Psychiatry·Michael Soyka, Jochen Mutschler
Feb 21, 2013·The American Journal of Drug and Alcohol Abuse·Ramakrishna NirogiRenny Abraham
Jun 12, 2013·Drug and Alcohol Dependence·Henri-Jean Aubin, Jean-Bernard Daeppen
Apr 22, 2016·Expert Opinion on Investigational Drugs·Giovanni MartinottiMassimo Di Giannantonio
Oct 12, 2014·Psychopharmacology·Rae A LittlewoodKent E Hutchison
Jan 1, 2011·International Journal of Psychiatry in Medicine·Peter M MillerScott H Stewart
Feb 2, 2012·Journal of Pharmacological Sciences·Masahiro ShibasakiSeitaro Ohkuma
Jun 10, 2016·Nature Reviews. Neuroscience·Markus HeiligYavin Shaham
Dec 23, 2016·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Michael SoykaUNKNOWN WFSBP Task Force on Treatment Guidelines for Substance Use Disorders
May 26, 2012·Journal of Psychopharmacology·A R Lingford-HughesUNKNOWN British Association for Psychopharmacology, Expert Reviewers Group
Jul 1, 2017·Expert Opinion on Pharmacotherapy·Michael Soyka, Christian A Müller
Dec 28, 2017·Alcohol and Alcoholism : International Journal of the Medical Council on Alcoholism·Carolina L Haass-KofflerRobert M Swift
Jan 25, 2018·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Joseph P SchachtRaymond F Anton
Feb 13, 2013·Journal of Korean Medical Science·Jee Wook KimIhn-Geun Choi
Feb 12, 2008·Alcoholism, Clinical and Experimental Research·Henry R KranzlerCheryl Oncken
Mar 3, 2018·Psychopharmacology·Laura B FergusonRoy Dayne Mayfield
Jul 16, 2010·Journal of Clinical Psychopharmacology·Simon ZhornitskyStéphane Potvin
Apr 23, 2010·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Erin N AdamsPhilip Bautista
Oct 14, 2017·Journal of Clinical Psychopharmacology·Robert J FeeleyGihyun Yoon
Jul 3, 2017·CNS Drugs·Andrew NaglichE Sherwood Brown
May 12, 2017·Alcoholism, Clinical and Experimental Research·Raymond F AntonPatrick K Randall

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.